 JanOne Inc NASDAQ: JAN has acquired an option agreement for the rights to a novel strategy to reduce methamphetamine meth use by activating the Translocator Protein 18 kDa TSPO. The agreement with LSU Health Shreveport and other intellectual property relating to TSPOs role in treating meth use disorder MUD provides JanOne with an opportunity to identify new drugs to enhance TSPO activity. 